Related Experiment Video
Updated: Feb 11, 2026

Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay
Published on: July 13, 2017
Baseline Anti-Dengue IgG Seroprevalence in a Pediatric Brazilian Population Before TAK-003 Vaccination
Amanda Maria Miguel Bortuluzi1, Paulo César Pereira Dos Santos2, Luana Clemm Kuhnen Anschau1
1Post Graduate Program in Health Sciences, Federal University of Grande Dourados, Dourados, Brazil.
Insights
Dengue IgG seroprevalence in Brazilian children aged 4-16 was 20.5%, increasing with age. Baseline data are crucial for guiding the TAK-003 vaccine strategy and monitoring risks.
Area of Science:
- Tropical Medicine
- Immunology
- Public Health
Background:
- Dengue is a significant public health issue in Brazil, causing frequent outbreaks.
- The TAK-003 vaccine presents a potential method for dengue control, especially in pediatric populations.
Purpose of the Study:
- To assess the baseline seroprevalence of anti-dengue IgG antibodies in children and adolescents in Dourados, Brazil.
- To inform the implementation and monitoring of the TAK-003 dengue vaccine.
Main Methods:
- Cross-sectional study involving 643 children and adolescents (4-16 years).
- Analysis of anti-dengue IgG seroprevalence using ELISA on capillary blood samples.
- Collection of sociodemographic data via questionnaires.
Main Results:
- Overall anti-dengue IgG seroprevalence was 20.5%.
- Seropositivity significantly increased with age, from 13.4% (4-8 years) to 27.7% (13-16 years).
- Male sex was associated with lower IgG levels.
Conclusions:
- Age-specific seroprevalence indicates cumulative dengue virus exposure in children and adolescents.
- Baseline seroprevalence data are essential for effective dengue vaccination strategies, assessing vaccine efficacy, and managing risks like antibody-dependent enhancement.
Abstract:
Dengue remains a major public health challenge in Brazil, with recurrent outbreaks placing a strain on healthcare systems. The TAK-003 vaccine offers a promising control strategy, particularly for children. This cross-sectional study evaluated the seroprevalence of anti-dengue IgG in 643 children and adolescents aged 4-16 years in Dourados, Brazil, before being administered the TAK-003 vaccine. Capillary blood samples were collected on filter paper and analyzed using ELISA; sociodemographic data were obtained through questionnaires. Overall, 20.5% of participants were seropositive. Seropositivity increased with age, with 27.7% among those aged 13-16 years testing positive compared with 13.4% among children aged 4-8 years. Male sex was associated with lower IgG levels. The age-related increase in anti-dengue IgG seroprevalence reflects cumulative exposure to the virus during childhood and adolescence, highlighting the need for immunization strategies tailored to age. These findings emphasize the importance of baseline anti-dengue IgG seroprevalence data to guide vaccination, assess effectiveness, and monitor antibody-dependent enhancement risks.
Related Concept Videos
Vaccinations
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Conservation of Small Populations
What is Population Genetics?
Population Growth
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

